Screening method utilizing thalidomide-targeting factor
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 22, 2015
Grant Date -
Jul 26, 2012
app pub date -
Oct 18, 2010
filing date -
Oct 20, 2009
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
With an aim to provide means for developing a compound devoid of teratogenicity but retaining beneficial actions, a screening method for a non-teratogenic substance comprising bringing a test substance into contact with cereblon or a fragment of cereblon, evaluating the bindability of the test substance with cereblon or the fragment of cereblon, and selecting a test substance that does not bind to cereblon or the fragment of cereblon or a test substance exhibiting lower bindability with cereblon or the fragment of cereblon than does thalidomide is provided.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully